文献速递骨肿瘤

术前地舒单抗联合刮除与冷冻治疗骨巨细胞瘤:局部复发风险是否增加?

Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

本研究回顾性比较了21例骨巨细胞瘤患者接受术前地舒单抗后刮除冷冻治疗与单纯刮除冷冻治疗的局部复发率和不良反应。地舒单抗组12例中5例复发,单纯手术组9例中1例复发,差异无统计学意义(p=0.18)。未观察到地舒单抗相关不良反应,但研究样本量小、把握度不足。

要点

  • 地舒单抗组局部复发5/12例,单纯手术组1/9例,差异无统计学意义(p=0.18)。
  • 未发现地舒单抗相关电解质、血常规、肝肾功能异常或颌骨坏死。
  • 作者认为刮除可行时,初次病灶内手术不使用地舒单抗似乎更谨慎。

核心结论

  • 在小样本中,术前使用地舒单抗似乎可使肿瘤周围形成骨性边缘,可能有助于部分患者行刮除而非骨关节切除。
  • 未观察到地舒单抗降低局部复发风险,提示其可能不降低疾病侵袭性。
  • 根据初步结果,不能排除地舒单抗治疗患者刮除后局部复发率甚至高于未治疗患者。
  • 除非更大规模研究证实可降低复发,否则初次刮除可行时,不使用地舒单抗的初次病灶内手术似乎更谨慎。
  • 未观察到地舒单抗不良反应,但本研究把握度不足,无法检测甚至相对常见的并发症和相对较大的局部复发风险差异。

研究设计与样本

  • 回顾性评估2009年6月至2016年6月在本机构接受刮除与冷冻治疗的骨巨细胞瘤患者。
  • 比较术前地舒单抗后刮除冷冻治疗(12例)与单纯刮除冷冻治疗(9例),共纳入21例。
  • 冷冻治疗使用氩冷冻探针至-150°C,随后使用骨水泥(17例)或莫氏化同种异体骨(4例)。
  • 地舒单抗组中位随访39个月(范围14-55个月),单纯手术组27个月(范围18-92个月)。
  • 证据等级为III级,治疗性研究。

主要发现

  • 地舒单抗组12例中5例局部复发,单纯手术组9例中1例局部复发(p=0.18)。
  • 地舒单抗组12例中8例为Campanacci 3级,单纯手术组9例中2例为Campanacci 3级(p=0.08)。
  • 两组骨骺近关节骨受累范围在现有样本量下无差异。
  • 未发现地舒单抗治疗期间或治疗后相关不良反应,包括电解质水平、血细胞计数、肝肾功能参数无改变。
  • 本小样本中无患者发生颌骨坏死。

关键数值与推荐

  • 局部复发比例:地舒单抗组5/12 vs 单纯手术组1/9(p=0.18)。
  • Campanacci 3级比例:地舒单抗组8/12 vs 单纯手术组2/9(p=0.08)。

临床怎么用

  • 作者认为,当就诊时刮除可行时,初次病灶内手术不使用地舒单抗似乎更谨慎。
  • 作者指出,未来应前瞻性评估地舒单抗,鉴于该肿瘤相对罕见,可能需要多中心研究。

局限性

  • 本研究为回顾性评估。
  • 本研究样本量小(21例)。
  • 本研究把握度不足,无法检测甚至相对常见的并发症和相对较大的局部复发风险差异。
  • 作者指出不能排除地舒单抗治疗患者刮除后局部复发率甚至高于未治疗患者。
  • 作者建议未来需前瞻性研究,并可能需要多中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Denosumab is a monoclonal RANKL antibody, which was originally introduced for the treatment of osteoporosis and bone metastases from solid tumors, but more recently has been used for treatment of giant cell tumor of bone (GCTB). In GCTB, denosumab has been used as a single agent in patients with inoperable tumors; it also has been used before surgery in some patients with the aim to downstage the tumor to facilitate a joint-preserving procedure (curettage) rather than a resection. However, few studies are available evaluating the benefits and risks of denosumab for the latter indication. QUESTIONS/PURPOSES: (1) Does preoperative treatment with denosumab reduce the risk of local recurrence in patients treated for GCTB? (2) Are there adverse effects of short-term denosumab use before surgery and, if so, what are they? METHODS: All patients with a diagnosis of GCTB surgically treated at our institution from June 2009 to June 2016 with curettage and cryotherapy were retrospectively evaluated to compare patients treated with curettage alone versus patients treated with curettage after preoperative therapy with denosumab. During that period, we treated 97 patients for GCTB; 30 patients were excluded because they received a resection; 34 patients were excluded because they received curettage without cryotherapy. Of the remaining 33 patients, four were excluded because they received denosumab only after surgery, one because she received zoledronic acid, one because she received a curettage after her refusal of a resection that was the advised procedure, two because they were lost to followup early, and four because they were treated for recurrence rather than a new diagnosis of GCTB. The remaining 21 patients were included. Twelve lesions had been treated with surgery after denosumab and nine with surgery alone. During the study period, we preferentially used denosumab for the more aggressive-looking lesions. After curettage, cryotherapy of the residual bone walls was performed with argon cryoprobes to -150° C after pouring gel into the cavity, and we then used cement (17 patients) or morcellized allograft (four patients). Tumors were Campanacci Grade 3 in eight of 12 patients in the denosumab group and in two of nine patients in the surgery-only group (p = 0.08), but the extent of epiphyseal juxtaarticular bone involvement was not different between the groups with the numbers available. Median followup was 39 months (range, 14-55 months) in the denosumab group and 27 months (range, 18-92 months) in the surgery-only group. We used chart review to record the proportion of patients in each treatment group who had a local recurrence and to tally adverse events. RESULTS: With the numbers available, there was no difference in the proportion of patients experiencing a recurrence (five of 12 in the denosumab group and one of nine in the surgery-only group; p = 0.18). We found no adverse effects associated with denosumab either during or after treatment; specifically, we found no alterations in electrolyte levels, blood count, or liver and renal function parameters. In this small series, no patient has developed osteonecrosis of the jaw. CONCLUSIONS: In this small series, use of denosumab before surgery for GCTB appeared to allow the reforming of a bone peripheral rim around the tumor, perhaps facilitating curettage rather than osteoarticular resection in some patients. However, we did not observe a decrease in the risk of local recurrence with the use of denosumab, suggesting that it may not decrease the aggressiveness of the disease; according to our preliminary results, we cannot exclude that the rate of local recurrence could be even higher after curettage in denosumab-treated patients than in nontreated patients, and until or unless larger studies demonstrate such a reduction, primary intralesional surgery without denosumab seems more prudent when curettage is feasible at presentation. We did not observe any adverse effects with denosumab, but we caution readers that this study was underpowered to detect even relatively common complications and relatively large differences in the risk of local recurrence. Future studies should evaluate denosumab prospectively; given the relative rarity of this tumor, we suspect multicenter studies are needed to achieve this. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Scoccianti G, Totti F, Scorianz M, et al. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence? Clin Orthop Relat Res. 2018. PMID: 30778015. doi:10.1007/s11999.0000000000000104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。